In January 2026, the General Pharmaceutical Council published updated inspection guidance covering weight-loss medications, online pharmacies, and prescribing standards
By modulating the CDK1(cyclin dependent kinase 1)-APC/C (ubiquitin ligase)-Cdh1 (ubiquitin ligase activator) signaling pathway after PPAR activation, bergenin inhibited GLS1-dependent Gln catabolism, thereby inhibiting Th17 differentiation and significantly reducing the number of neutrophils in the BALF of neutrophilic asthmatic mice and the infiltration of inflammatory cells around bronchi in the lungs of mice with neutrophilic asthma (95) ( Table 1 )
#ClinicalTrials #DrugDevelopment #Diabetes #GLP #Weightloss To view or add a comment, sign in Treatment-Resistant Hypertension market is projected to grow at a CAGR of 6.30% by 2034, Companies: Idorsia, Janssen Biotech, Quantum Genomics, CinCor Pharma, Ionis Pharmaceuticals, Vifor Pharma, KBP: Treatment-Resistant Hypertension market Treatment-Resistant Hypertension market size in the 7MM was valued at approximately USD 6,958 million in 2025
"Best Practices for Medication Storage and Handling in Home Settings." American Journal of Health-System Pharmacy, 78(14), 1312-1324
